This photo provided by AstraZeneca shows a bottle of Lynparza. On Friday, Jan. 12, 2018, the Food and Drug Administration approved AstraZeneca PLC&#8217;s Lynparza, the first drug aimed at women with advanced breast cancer caused by an inherited flawed gene. (Courtesy of AstraZeneca via AP)